重组人神经生长因子治疗大鼠糖尿病周围神经病变的效果
2015-08-06章永垒等
章永垒等



[摘要] 目的 观察重组人神经生长因子(rhNGF)治疗大鼠糖尿病周围神经病变(DPN)效果。 方法 选用健康成年的雄性SD大鼠,腹腔注射链脲霉素(STZ)建立糖尿病(DM)大鼠模型。1个月后检测大鼠尾部感觉神经传导速度(SNCV),以SNCV<30 m/s为DPN成模标准。将DPN大鼠随机分为6组,分别为模型对照组、受试药rhNGFⅠ、Ⅱ、Ⅲ、Ⅳ(剂量分别为0.3、1、3、9 μg/kg)4个剂量组,阳性对照组(依帕司他15 mg/kg),同时设正常对照组。连续给药2个月,检测大鼠体重、血糖、大鼠尾部SNCV、坐骨神经传导速度(MNCV)以及坐骨神经中果糖及山梨醇含量。 结果 DM造模1个月后,模型对照组大鼠体重、血糖值、尾部SNCV和坐骨神经MNCV均与正常对照组有明显差异(P < 0.01),表明DPN造模成功。受试药rhNGF对DPN大鼠体重和血糖值无显著影响(P > 0.05),对大鼠尾部SNCV和坐骨神经MNCV具有明显改善作用,给药2个月rhNGF受试组(Ⅲ)大鼠尾部SNCV、rhNGF受试组(Ⅱ、Ⅲ)坐骨神经MNCV较模型对照组高且差异有统计学意义(P < 0.05)。DPN大鼠坐骨神经中果糖及山梨醇的含量显著升高,说明DPN的发生与多元醇代谢紊乱具有相关性。受试药rhNGF能降低DPN大鼠坐骨神经中果糖及山梨醇的含量,其中果糖含量变化具有一定的剂量相关性,而山梨醇含量变化未发现明显的剂量效应。 结论 受试药rhNGF对DPN大鼠神经具有较好的保护作用,与阳性对照药依帕司他作用相似,可能与改善DPN大鼠的多元醇代谢相关。
[关键词] 糖尿病;糖尿病周围神经病变;神经生长因子;神经传导速度;山梨醇;果糖
[中图分类号] R745 [文献标识码] A [文章编号] 1673-7210(2015)06(c)-0004-05
Therapeutic effect of recombinant human nerve growth factor on rats with diabetic peripheral neuropathy
BAI Yang ZHANG Yonglei HUANG Fenfei CHEN Shengliang RUAN Ka CHEN Xing▲
SinoBioway Biomedicine Co., Ltd., Fujian Province, Xiamen 361009, China
[Abstract] Objective To observe the therapeutic effect of recombinant human nerve growth factor (rhNGF) on diabetic peripheral neuropathy (DPN) rats. Methods Healthy adult male SD rats were induced to diabetes rats by intramuscular injection of streptozotocin. After a month, rats with the tail sensory nerve conduction velocity (SNCV) <30 m/s were confirmed as DPN model rats. DPN rats were randomly divided into six groups, including the model control group, the investigational drug rhNGF Ⅰ, Ⅱ, Ⅲ, Ⅳ (doses of 0.3, 1, 3, 9 μg/kg) 4 dose groups and the positive control group (epalrestat 15mg/kg), concomitantly with the normal control group. During the administration of 2 months, body weight of rats were detected weekly, blood glucose and SNCV monthly, sciatic nerve conduction velocity (MNCV) was detected after the last administration, and levels of sorbitol and fructose in sciatic nerve were last measured. Results Body weight, blood glucose, SNCV and MNCV of the model control group were significantly different with the normal control group after a month (P < 0.01), showed that the successful modeling of DPN. The investigated drug rhNGF and the positive drug epalrestat had no significant effect on body weight and blood glucose of DPN rats (P > 0.05), but improved SNCV and MNCV. At 2 month, SNCV in rhNGF group (Ⅲ) and MNCV in rhNGF group (Ⅱ, Ⅲ) were significantly higher than the model control group (P < 0.05). Levels of fructose and sorbitol in sciatic nerve raised in DPN rats, indicated the relationship between DPN and polyol metabolism. rhNGF reduced fructose and sorbitol in sciatic nerve, with dose effect in fructose but not in sorbitol. Conclusion rhNGF has a significant protective effect on nerve of DPN rats, which may be associated with improvement of polyol metabolism similar with epalrestat.
[Key words] Diabetes mellitus; Diabetic peripheral neuropathy; Recombinant human nerve growth factor; Nerve conduction velocity; Sorbitol; Fructose
糖尿病(diabetes mellitus,DM)是常见的代谢性疾病,据估计我国约有11.6%的成人患有DM[1]。糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)是DM最常见的慢性并发症之一[2]。应用外源性神经生长因子(nerve growth factor,NGF)有助于DPN症状减轻[3],临床上可有效地改善DPN的神经症状、血清蛋白含量和血液流变学[4-8]。但目前国内使用的NGF主要来源为天然提纯,与天然NGF相比,重组人神经生长因子(recombinant human nerve growth factor,rhNGF)具有易获得、高产率、高活性与低成本等特点[9]。本文对DPN大鼠给予rhNGF治疗,对治疗前后体重、血糖值、大鼠尾部感觉神经传导速度(sensory nerve conduction velocity,SNCV)和坐骨神经运动神经传导速度(motor nerve conduction velocity,MNCV)以及大鼠坐骨神经中果糖、山梨醇含量进行了比较,对rhNGF对大鼠DPN的治疗效果进行了研究。
1 材料与方法
1.1 实验材料
体重200~250 g的健康雄性SPF级SD大鼠,由南方医科大学实验动物中心提供(动物质量合格证号:44002100003545)。rhNGF(未名生物医药有限公司,批号:BW101),采用E.coli重组表达[10],HPLC检测纯度>98.0%,TF-1细胞法检测体外生物学活性>500 AU/μg。
1.2 仪器与试剂
T1000Y电子天平(美国双杰兄弟公司)、BS211D型电子天平(德国Sartorius公司)、BL-420F生物机……
